From July this year, some psychiatrists will be able to prescribe psychedelics to some patients. Responses from experts working in the field are mixed.
Articles on Psychedelics
Displaying 41 - 60 of 72 articles
Alberta’s new policy on psychedelic-assisted therapy for mental illness may set a precedent that moves Canadians one step closer to accepting psychedelics as medicinal substances.
Flickering light can make people see different colours and shapes or feel altered emotions or sense of time.
Today’s psychedelics researchers still have to deal with the fallout of the decadeslong freeze on research. Listen to ‘The Conversation Weekly’ podcast.
There is a lot of hype in psychedelics research at the moment. Here’s how to tell which research is good and which isn’t.
The active compound in magic mushrooms seems to increase connections between different brain networks.
Pinpointing the molecular targets behind the subjective effects of psychedelic drugs could help clinicians and researchers better treat psychiatric conditions.
Growing interest in psychedelics has spurred new research decades after hallucinogenics were tested in Saskatchewan in the 1950s. And an unassuming common fish is proving a useful test subject.
Nine Perfect Strangers tries to be a satire on wellness culture — and yet celebrates its trappings all the same.
Microdosing involves taking a low dose of a psychedelic drug to enhance performance, or reduce symptoms of stress and anxiety. Here’s what our research shows.
Psychedelics use is on the rise and it’s partly due to a wellbeing rebrand.
The TGA is currently evaluating a proposal to legalise MDMA and psilocybin for the treatment of mental illness. But there are a few reasons Australia isn’t quite ready to take this step.
How on earth did an obscure Roman social practice end up lending its name to a modern psychedelic?
Psychedelic drugs are creating waves as evidence mounts of their therapeutic potential. New research also suggests they might mitigate the climate crisis by unlocking a lost connection to nature.
In a new research study, more than 900 people from around the world explain the challenges and benefits of microdosing LSD and psilocybin-containing mushrooms.
Ketamine and other psychedelics are being licensed for medical use – two experts advise how to minimise harm for users.
Before being qualified as “magic”, certain mushrooms were considered sacred by the ancient peoples of Mexico. We explore their history and relationship to Mesoamerican religion and medicine.
Most people assume drugs are illegal because they are dangerous, but the reasons aren’t related to their relative risk or harm.
Research shows therapeutic psilocybin to be a safe and effective antidote to end-of-life anxiety and depression. Does prohibition therefore violate our right to “life, liberty and security?”
According to new research, individuals who take small regular doses of psychedelics such as LSD and psilocybin mushrooms score higher on mental health, well-being and creativity.
Top contributors
-
Senior Lecturer of Addiction, Edith Cowan University
-
PhD Candidate, Congnitive Neuroscience, University of Toronto
-
PhD student in Clinical Psychology, York University, Canada
-
Associate Professor, Cognitive Psychology, Leiden University
-
Director, Executive Leadership Academy, University of California, Berkeley
-
Professor and Canada Research Chair in the History of Health & Social Justice, University of Saskatchewan
-
Distinguished Professor of Neurology and Psychiatry, Director of Psychedelics Division at Neuroscape, University of California, San Francisco
-
Research fellow, Swinburne University of Technology
-
Research Assistant in Psychiatry, University of Cambridge
-
Senior Clinical Lecturer & Consultant Psychiatrist, King's College London
-
Professor, Brain Institute, Universidade Federal do Rio Grande do Norte (UFRN)
-
Universidade Federal do Rio Grande do Norte (UFRN)
-
Assistant Professor, Department of Chemistry; Department of Biochemistry & Molecular Medicine; Center for Neuroscience, University of California, Davis
-
Professor of Neuropsychopharmacology, Imperial College London
-
Associate Professor, Behavioural Pharmacology Research Unit, Johns Hopkins University